This presentation examines the advantages of using multiparticulates as a pediatric dosage form, particularly early in the drug-development process. Often development of age-appropriate dosage forms does not begin until after proof of concept, but a case study is presented showing how lipid multiparticulates can be used in early-stage development, speeding time to clinic and minimizing the use of valuable active ingredient. To learn more, please see our presentation.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center